• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / No Link Between RA Therapy and Lymphoma Observed in Large Cohort of Rheumatoid Arthritis Patients

No Link Between RA Therapy and Lymphoma Observed in Large Cohort of Rheumatoid Arthritis Patients

June 19, 2007 By Arthritis Center

Individuals with rheumatoid arthritis (RA) are at an increased risk for lymphoma compared to the general population, with the risk increasing in proportion to cumulative exposure to systemic inflammation.  Whether RA therapies, such as biologic and non-biologic DMARDs, contribute to this risk is controversial.  Here, Wolfe et al (Arthritis Rheum 2007; 56: 1433) explore lymphoma risk in a large cohort of DMARD treated RA patients.

Methods

Subjects were participants in the National Data Bank for Rheumatic Diseases (NDB) in which patients with RA are followed longitudinally with semiannual patient-derived questionnaires, including RA medications and incident comorbidities (such as new lymphoma diagnosis).  Reports of incident lymphomas were confirmed with medical records.  Incidence rates for lymphoma in RA subjects were compared to the U.S. Surveillance, Epidemiology, and End-Results (SEER) database and within RA subjects according to treatment allocation, with conditional logistic regression used to account for entry time into the study.

Results

19,562 RA subjects with a total of 89,710 person-years of observation were analyzed.  The majority of subjects were female (77%) with an average age at enrollment of 59 ± 13.2 years and an average RA duration at enrollment of 14.1 ± 12.1 years.  More that half (55.3%) of subjects received a biologic DMARD during follow-up and 68% received methotrexate.  Of the biologics represented, infliximab was the most frequent (40.3%) followed by etanercept (19.2%) and adalimumab (7.6%).  Prednisone was used in 45.7% of subjects at enrollment.

Among the RA cohort there were 95 incident lymphoma cases corresponding to an incidence rate of 106 per 100,000.  Compared to the SEER registry, the expected number of incident cases was 52.2, resulting in a standardized incidence ratio (SIR) of 1.8 (95% CI 1.5 – 2.2).  Treatment with TNF inhibitors as a class, or analyzed by specific agent, were not associated with an increased risk of lymphoma either with or without the consideration of concomitant medications or the timing of the TNF inhibitor within the treatment course.

Conclusions

While RA was associated with an increased risk of incident lymphoma, TNF inhibitor therapy was not a significant contributor to the increased risk observed.

Editorial Comment

These findings contrast with a recent report of post hoc analyses from clinical trials of infliximab and etanercept than identified an increased and early risk of malignancy (including solid tumors, hematologic malignancies, and non-melanoma skin cancers) in RA patients compared to placebo.  The data presented here have the advantage of involving a larger cohort with longer follow-up and a more representative sample of subjects cared for in clinical practice.  While the techniques used to account for non-random treatment assignment are an advantage of this study compared to other observational studies, they cannot completely control for the effect of confounding by indication.  However, as biologic DMARD treated patients often have more disease activity and systemic inflammation than those not treated in clinical practice, they are also those most at risk for comorbidities related to disease activity and inflammation, such as lymphoma.  The findings here are reassuring that biologics do not appear to contribute to this risk, either by themselves or combined with other DMARDs.  However, continued vigilance is required, particularly as a substantial number of biologic treated patients are entering into their second decade of use.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy